Search Results - "Dai, Yong M."

18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer by Guan, Jian, Xiao, Nan J., Chen, Min, Zhou, Wen L., Zhang, Yao W., Wang, Shuang, Dai, Yong M., Li, Lu, Zhang, Yue, Li, Qin Y., Li, Xiang Z., Yang, Mi, Wu, Hu B., Chen, Long H., Liu, Lai Y.

“…Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) are a response to EGFR-tyrosine kinase inhibitor. However, a lack of…”
Get full text

Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects by Deng, Sheng, PhD, MD, Chen, Xiao-Ping, PhD, MD, Cao, Dan, MD, Yin, Tao, PhD, Dai, Zhi-Yong, MD, Luo, Jian, MD, Tang, Ling, MD, Li, Yuan-Jian, MS, MD

“…Abstract Background: Pravastatin is a potent cholesterol-lowering agent; ~34% of an oral dose of pravastatin is eliminated unchanged through biliary and…”
Get full text

Effects of Angiotensin Receptor Blocker on Phenotypic Alterations of Podocytes in Early Diabetic Nephropathy by Dai, Hou-Yong, MD, Zheng, Min, MD, Tang, Ri-Ning, MD, Ni, Jie, MD, Ma, Kun-Ling, PhD, Li, Qing, MD, Liu, Bi-Cheng, MD, PhD

“…Abstract Background Emerging evidence suggests that podocyte injury is a crucial event in the stage of diabetic nephropathy (DN), a process in which…”
Get full text